
Teleflex Incorporated
TFXNYSEHealthcareMedical - Instruments & Supplies
Previous close
$138.83
+$3.87 · +2.87%
TFX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
54
Fair Value
Momentum
50
Neutral
Sentiment
68
Bullish
Risk resilience
76
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteTeleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jason Weidman
- Listed since
- Mar 17, 1980
- Employees
- 15,500
Market position
Day range
Current $138.83
52-week range
Current $138.83
- Open
- $133.31
- Previous close
- $134.96
- Volume
- 630.89K
- 0.94× average
- Average volume
- 672.47K
- Average daily volume
- Market cap
- 6.15B USD
- Beta
- 0.81
- Market reference 1
- 50-day average
- $132.65
- +4.66% above average
- 200-day average
- $121.75
- +14.03% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 7.78B USD
- P/E (TTM)
- -5.96×
- P/B (TTM)
- 2.08×
- P/S (TTM)
- 2.36×
- EV / EBITDA
- 25.71×
- Earnings yield
- -16.63%
- Free cash flow yield
- 4.51%
- Dividend yield
- 0.98%
Profitability & efficiency
- Gross margin
- 53.77%
- Operating margin
- 3.35%
- Net margin
- -39.58%
- Return on equity
- -28.98%
- Return on assets
- -13.04%
- Return on invested capital
- 4.07%
Financial health
- Debt / equity
- 0.99×
- Current ratio
- 2.54×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.99B USD | 3.05B USD | 2.97B USD | 2.79B USD | 2.81B USD |
| Cost of goods sold | 871.96M USD | 1.34B USD | 1.33B USD | 1.26B USD | 1.26B USD |
| Gross profit | 1.12B USD | 1.7B USD | 1.65B USD | 1.53B USD | 1.55B USD |
| Research and development | 144.78M USD | 161.67M USD | 154.35M USD | 153.82M USD | 130.84M USD |
| Selling, general, and administrative | 720.17M USD | 995.27M USD | 929.87M USD | 863.75M USD | 860.09M USD |
| Operating expenses | 864.95M USD | 1.55B USD | 1.14B USD | 1.03B USD | 921.51M USD |
| Interest income | 6.4M USD | 8.01M USD | 12.78M USD | 912K USD | 1.33M USD |
| Interest expense | 100.22M USD | 83.54M USD | 85.08M USD | 54.26M USD | 56.97M USD |
| Depreciation and amortization | 177.74M USD | 274.6M USD | 242.12M USD | 230.59M USD | 237.36M USD |
| Operating income | 255.8M USD | 151.01M USD | 506.31M USD | 499.73M USD | 628.1M USD |
| Net income | −905.64M USD | 69.68M USD | 356.33M USD | 363.14M USD | 485.37M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 91%
- 10 beats, 1 miss, 0 met estimates
- Average EPS surprise
- +3.61%
- 11 comparable reports
- Latest EPS result
- 1.76
- Estimate 1.28 · Beat by 37.50%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
29 ratingsRecent analyst actions
TFX peers
ETFs holding TFX
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR358.59M0.32%111.19B USD0.06%$147.31+0.64%
Vanguard Morningstar Total Stock Market ETFVTI192.61M0.01%2.3T USD0.03%$378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB139.16M0.08%183.4B USD0.03%$304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR88.37M0.13%68.3B USD0.05%$249.18+0.68%
Vanguard Extended Market ETFVXF69.73M0.07%93.7B USD0.05%$245.53+0.82%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM56.39M0.33%17.03B USD0.03%$57.28+0.61%
iShares S&P Small-Cap 600 Value ETFIJS52.43M0.62%8.33B USD0.18%$138.43+0.67%
State Street SPDR S&P 600 Small Cap Value ETFSLYV32.26M0.64%5.03B USD0.15%$110.42+0.66%
iShares Core S&P Small-Cap ETFIJR- Market value
- 358.59M
- Weight
- 0.32%
- AUM
- 111.19B USD
- Expense ratio
- 0.06%
- Price / 1D
- $147.31+0.64%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 192.61M
- Weight
- 0.01%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 139.16M
- Weight
- 0.08%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR- Market value
- 88.37M
- Weight
- 0.13%
- AUM
- 68.3B USD
- Expense ratio
- 0.05%
- Price / 1D
- $249.18+0.68%
Vanguard Extended Market ETFVXF- Market value
- 69.73M
- Weight
- 0.07%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM- Market value
- 56.39M
- Weight
- 0.33%
- AUM
- 17.03B USD
- Expense ratio
- 0.03%
- Price / 1D
- $57.28+0.61%
iShares S&P Small-Cap 600 Value ETFIJS- Market value
- 52.43M
- Weight
- 0.62%
- AUM
- 8.33B USD
- Expense ratio
- 0.18%
- Price / 1D
- $138.43+0.67%
State Street SPDR S&P 600 Small Cap Value ETFSLYV- Market value
- 32.26M
- Weight
- 0.64%
- AUM
- 5.03B USD
- Expense ratio
- 0.15%
- Price / 1D
- $110.42+0.66%
Continue in GoAI
Research TFXresearch.disclaimer





